Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Pao Pereira has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Pao pereira bark carries indole and beta-carboline-type alkaloids, and beta-carbolines as a chemical class inhibit monoamine oxidase A in laboratory systems. 5-HTP raises serotonin synthesis. Slowing breakdown while raising synthesis pushes the same pool from two sides, which is a caution, not a stack. No human pharmacokinetic work exists on this specific bark, so the confidence sits on the class rather than the plant.
The same reasoning as for 5-HTP applies one step earlier in the pathway. Tryptophan feeds serotonin synthesis, and beta-carboline alkaloids reduce the enzymatic clearance of monoamines in laboratory systems. The overlap is worth flagging on direction. It has not been measured in people taking this bark.
Hypericum affects serotonin handling and separately induces CYP3A4 and P-glycoprotein strongly. Combining it with an alkaloid-bearing bark creates two problems at once: overlapping monoamine effects, and altered clearance of the alkaloids themselves. Neither has been quantified for this bark. Listed as a caution.
SAM-e is a methyl donor involved in catecholamine and serotonin metabolism, and beta-carboline alkaloids act on the enzymes clearing those same monoamines. The pathways intersect enough to be worth naming. There is no human data on the pairing and the reasoning is entirely mechanistic.
Indole alkaloids of this class have been described as producing sedation in animal work, and melatonin lowers alertness at the doses commonly used. The direction of the overlap is toward more sedation, which matters for driving and machinery. This is class reasoning, not a measured interaction for this bark.
Alkaloids of this class are cleared hepatically, and silymarin inhibits UGT and CYP3A4 in laboratory systems. That predicts altered alkaloid exposure in either direction depending on the dominant route. Nothing has been measured for this bark, which is precisely why the pairing deserves caution rather than confidence.
Nothing specific on file for Pao Pereira. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.